A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant (CMV-IMPACT)

NCT01077908 Phase 3 COMPLETED

The purpose of this study is to evaluate the potential clinical benefit of prophylactic cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) for reducing recurrent CMV reactivation.

Details

Lead sponsor	Cell Medica Ltd
Phase	Phase 3
Status	COMPLETED
Enrolment	89
Start date	2008-07
Completion	2014-10

Conditions

• Cytomegalovirus Infection

Interventions

• Adoptive Cellular Therapy
• Best available antiviral drug therapy

Primary outcomes

• CMV reactivations — Six months

Countries

United Kingdom